MCID: CHR100
MIFTS: 57

Chronic Ulcer of Skin

Categories: Skin diseases

Aliases & Classifications for Chronic Ulcer of Skin

MalaCards integrated aliases for Chronic Ulcer of Skin:

Name: Chronic Ulcer of Skin 40 12 15 37 17
Chronic Wounds 40 62
Indolent Ulcer 12
Callous Ulcer 12
Chronic Ulcer 70

Classifications:



External Ids:

Disease Ontology 12 DOID:8549
ICD9CM 34 707
SNOMED-CT 67 156423009
ICD10 32 L98.4
UMLS 70 C0157738 C0333297

Summaries for Chronic Ulcer of Skin

PubMed Health : 62 About chronic wounds: Minor injuries to our skin usually heal quite quickly on their own. Larger wounds may need more time, and sometimes stitches are needed. But some wounds close very slowly, keep on opening up, or do not heal at all. This is often a result of circulation problems or diabetes. Poorly healing wounds are more common on the lower legs or feet. Doctors refer to a wound that that does not heal for a long time as a chronic wound. Treatment often takes a long time and can be very painful. But it is important to have good wound care and to treat the underlying condition that caused the chronic wound to develop.

MalaCards based summary : Chronic Ulcer of Skin, also known as chronic wounds, is related to ulcer of lower limbs and venous insufficiency. An important gene associated with Chronic Ulcer of Skin is FGF2 (Fibroblast Growth Factor 2), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Octenidine and Benzalkonium Compounds have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and bone marrow, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Chronic Ulcer of Skin

Diseases related to Chronic Ulcer of Skin via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 764)
# Related Disease Score Top Affiliating Genes
1 ulcer of lower limbs 31.4 VEGFA TNF IL6 IL1B FGF2
2 venous insufficiency 31.1 VEGFA MMP1 CRP
3 gastrointestinal ulceration, recurrent, with dysfunctional platelets 30.9 PDGFB FGF2 EGF
4 chronic venous insufficiency 30.6 VEGFA TIMP2 MMP1 CRP
5 peripheral vascular disease 30.4 VEGFA IL6 CRP ALB
6 osteomyelitis 30.4 TNF IL6 IL1B CRP
7 pyoderma 30.3 TNF MMP1 IL1B CRP
8 fasciitis 30.3 TNF MMP1 IL6
9 polyarteritis nodosa 30.3 IL6 FGF2 CRP
10 vasculitis 30.3 TNF IL6 ELANE CRP
11 anal fistula 30.0 TNF EGF CRP
12 substance abuse 29.9 INS IL6 CRP ALB
13 limb ischemia 29.8 VEGFA TNF TIMP2 IL6 FGF2
14 periodontitis, chronic 29.8 MMP8 MMP1 IL6 IL1B
15 spondyloarthropathy 1 29.7 TNF IL6 CRP
16 cellulitis 29.7 TNF INS IL6 CRP ALB
17 bacterial infectious disease 29.6 TNF IL6 IL1B ELANE CRP
18 erysipelas 29.6 TNF IL6 IL1B ELANE CRP
19 acne 29.6 TNF INS IL6 IL1B
20 peripheral artery disease 29.6 VEGFA TNF IL6 FGF2 CRP
21 contact dermatitis 29.6 TNF NGF IL6 IL1B
22 endocarditis 29.6 TTR TNF IL6 CRP ALB
23 necrotizing fasciitis 29.5 IL6 IL1B FN1 CRP ALB
24 spondylitis 29.5 TNF IL6 IL1B CRP
25 systemic scleroderma 29.5 TNF INS IL6 FN1 CRP
26 vascular disease 29.5 VEGFA TNF INS IL6 FN1 FGF2
27 autoimmune disease 29.5 TNF INS IL6 IL1B CRP
28 tetanus 29.4 TNF IL6 IL1B CRP ALB
29 sickle cell anemia 29.3 TNF IL6 IL1B CRP ALB
30 disease by infectious agent 29.3 TNF IL6 IL1B CRP ALB
31 arthropathy 29.2 TNF MMP13 MMP1 IL6 IL1B CRP
32 pneumonia 29.2 TNF IL6 IL1B ELANE CRP ALB
33 mental depression 29.2 TNF INS IL6 IL1B CRP
34 periodontitis 29.1 TNF MMP8 MMP13 MMP1 IL6 IL1B
35 bone resorption disease 29.0 TNF INS IL6 IL1B CRP ALB
36 sleep disorder 29.0 TNF INS IL6 IL1B CRP ALB
37 basal cell carcinoma 29.0 VEGFA TNF MMP13 MMP1 IL6 IL1B
38 neuropathy 29.0 VEGFA TTR TNF NGF INS ALB
39 decubitus ulcer 28.9 VEGFA TTR TNF PDGFB OSCAR NGF
40 keratitis, hereditary 28.9 VEGFA TNF NGF IL6 IL1B FGF2
41 sleep apnea 28.8 VEGFA TNF INS IL6 IL1B CRP
42 anxiety 28.7 TNF NGF INS IL6 IL1B CRP
43 psoriasis 28.6 TNF NGF IL6 IL1B FGF7 ELANE
44 cystic fibrosis 28.5 TNF INS IL6 IL1B FN1 ELANE
45 skin disease 28.5 VEGFA TNF MMP1 INS IL6 IL1B
46 skin carcinoma 28.2 VEGFA TNF MMP1 INS IL6 IL1B
47 diabetes mellitus 27.8 VEGFA TTR TNF MMP8 MMP1 INS
48 peripheral nervous system disease 27.4 VEGFA TTR TNF NGF INS IL6
49 adamantinoma of long bones 10.4 FGF2 EGF
50 rapidly involuting congenital hemangioma 10.4

Comorbidity relations with Chronic Ulcer of Skin via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Peripheral Vascular Disease
Protein-Energy Malnutrition Schizophreniform Disorder

Graphical network of the top 20 diseases related to Chronic Ulcer of Skin:



Diseases related to Chronic Ulcer of Skin

Symptoms & Phenotypes for Chronic Ulcer of Skin

MGI Mouse Phenotypes related to Chronic Ulcer of Skin:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.36 ALB CRP FGF2 FN1 IL1B IL6
2 homeostasis/metabolism MP:0005376 10.36 ALB CRP ELANE FGF2 FGF7 FN1
3 immune system MP:0005387 10.27 ALB CRP EGF ELANE FGF7 FN1
4 hematopoietic system MP:0005397 10.21 ELANE FGF2 FGF7 FN1 IL1B IL6
5 integument MP:0010771 10.1 EGF ELANE FGF7 FN1 IL1B IL6
6 muscle MP:0005369 9.91 ALB FGF2 FN1 IL6 INS NGF
7 neoplasm MP:0002006 9.85 ALB ELANE FGF2 FN1 IL1B IL6
8 skeleton MP:0005390 9.65 FGF2 FGF7 FN1 IL1B IL6 INS
9 vision/eye MP:0005391 9.32 EGF FGF2 FGF7 IL6 INS NGF

Drugs & Therapeutics for Chronic Ulcer of Skin

PubMed Health treatment related to Chronic Ulcer of Skin: 62

Chronic wounds are covered with a dressing for protection. There are other treatment options in addition to regularly changing the wound dressing: Cleaning the wound Medical staff will change the wound dressing and clean the wound regularly. The wound is normally rinsed with a saline or electrolyte solution, or simply with tap water . A technique called debridement is used to remove dead cells or inflamed tissue with tweezers. Having a wound cleaned is often painful. A topical anesthetic such as a medicated ointment can be applied to the wound area to prevent pain. Larger wounds are sometimes cleaned under general anesthetic. Wound dressings After cleaning the wound , the doctor or nurse will put on a new dressing. Things like wet compresses, films or hydrogels are used as wound dressings. Their main purpose is to keep the wound moist, absorb excess fluid and prevent infection . Advanced treatments Some hospitals also use more advanced methods to help especially difficult wounds to heal: In hyperbaric oxygen therapy , patients sit in a special pressurized chamber and breathe in oxygen. In vacuum-assisted closure (VAC therapy ), fluid is continuously drawn out of the wound . Ultrasound therapy uses sound waves to treat chronic wounds . Electromagnetic therapy involves the use of magnetic cushions or mats that produce weak electric currents near the wound . Skin grafts Skin grafts may be an option for people with wounds that are too large to close on their own. The surgeon takes skin from another part of the body, often the upper leg, and transplants it to the wound . Grafts can also be made from human cell products and synthetic materials. Medication Good pain management is an important part of wound care. The pain caused by chronic wounds is often underestimated. Painkillers like acetaminophen (paracetamol) or ibuprofen tablets can help relieve mild to moderate pain. Your doctor can prescribe stronger painkillers if these do not provide enough relief. Wound dressings that contain ibuprofen are also available. Antibiotics can be used to treat wounds infected with bacteria .

Drugs for Chronic Ulcer of Skin (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octenidine Investigational Phase 4 71251-02-0
2 Benzalkonium Compounds Phase 4
3 Anti-Infective Agents, Local Phase 4
4 Pharmaceutical Solutions Phase 4
5 Anti-Infective Agents Phase 4
6
Becaplermin Approved, Investigational Phase 3 165101-51-9
7
Silicon Approved, Investigational Phase 2, Phase 3 7440-21-3 4082203
8
Morphine Approved, Investigational Phase 3 57-27-2 5288826
9 Mitogens Phase 3
10 Anticoagulants Phase 3
11 Angiogenesis Inducing Agents Phase 3
12 HIV Protease Inhibitors Phase 3
13
protease inhibitors Phase 3
14 Anti-Bacterial Agents Phase 3
15 Trace Elements Phase 2, Phase 3
16 Nutrients Phase 2, Phase 3
17 Micronutrients Phase 2, Phase 3
18 Narcotics Phase 3
19 Analgesics, Opioid Phase 3
20 Analgesics Phase 3
21
Ethanol Approved Phase 1, Phase 2 64-17-5 702
22
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2
23
Nystatin Approved, Vet_approved Phase 1, Phase 2 1400-61-9 11953884
24
Mupirocin Approved, Investigational, Vet_approved Phase 1, Phase 2 12650-69-0 446596
25
Bacitracin Approved, Vet_approved Phase 1, Phase 2 1405-87-4 439542 10909430
26
Methylene blue Approved, Investigational Phase 2 61-73-4
27
Nitric Oxide Approved Phase 2 10102-43-9 145068
28
Citric acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 77-92-9 311
29 Hematinics Phase 1, Phase 2
30 Epoetin alfa Phase 1, Phase 2 113427-24-0
31 Calcium, Dietary Phase 1, Phase 2
32 Citrate Phase 1, Phase 2
33 Gentian Phase 2
34
Gentian Violet Phase 2 14426-25-6 3468
35 Neurotransmitter Agents Phase 2
36 Vasodilator Agents Phase 2
37 Anti-Asthmatic Agents Phase 2
38 Respiratory System Agents Phase 2
39 Antioxidants Phase 2
40 Protective Agents Phase 2
41 Endothelium-Dependent Relaxing Factors Phase 2
42 Bronchodilator Agents Phase 2
43
Calcium Nutraceutical Phase 1, Phase 2 7440-70-2 271
44
Thrombin Approved, Investigational Phase 1
45 Vaccines Phase 1
46
Pancrelipase Approved, Investigational 53608-75-6
47
Coal tar Approved 8007-45-2
48
Aminolevulinic acid Approved 106-60-5 137
49
Neomycin Approved, Vet_approved 1404-04-2 8378
50
Polymyxin B Approved, Vet_approved 1404-26-8

Interventional clinical trials:

(show top 50) (show all 146)
# Name Status NCT ID Phase Drugs
1 A Prospective, Open Labelled, Multicentre Evaluation of the Use of EZCare◊ in the Management of Acute and Chronic Wounds Completed NCT00994162 Phase 4
2 Investigating the Effect of an Anti-Biofilm Solution to Reduce Bacterial Burden and Accelerate Healing in Chronic Wounds. Active, not recruiting NCT03686904 Phase 4 Benzalkonium Gel;benzalkonium irrigation
3 Randomized, Double-blind, Single-center, Placebo-controlled Study to Evaluate the Efficacy of Octenisept® in Patients With Chronic Wounds Terminated NCT01434914 Phase 4 octenisept®;Placebo
4 Restoring Equilibrium and Wound Stimulation to Promote Healing Of Non-healing DFUs Terminated NCT01608776 Phase 4
5 Clinical Outcomes for Chronic Ulcers Treated With Clostridial Collagenase (SANTYL®) Versus Standard Care Within the Continuum of Care of an Accountable Care Organization (ACO) Withdrawn NCT02716519 Phase 4
6 Chronic Venous ULcer TReatment Analyzing Bio-Electrical Stimulation Therapy Unknown status NCT00678847 Phase 2, Phase 3
7 Proof of Concept Study of Combined Topical Growth Factor and Protease Inhibitor in Chronic Wound Healing Unknown status NCT02845466 Phase 3
8 A Prospective, Multi-Center, Randomized, Controlled Clinical Investigation of Dermagraft(R) in Subjects With Venous Leg Ulcers DEVO-Trial Completed NCT00909870 Phase 3
9 A Prospective, Open, Non-controlled Proof-of-concept Investigation to Evaluate the Function of a New Silicon Cover Film and an On-top Suction Device to be Used in a NPWT System in the Treatment of Acute and Chronic Wounds Completed NCT01286857 Phase 2, Phase 3
10 Evaluation of a Medical Food for Chronic Wounds Completed NCT00711217 Phase 3
11 A Phase III Multicenter, Randomized, Double-Blind, Parallel-Group, Sham-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Wound Care in Lower Extremity Chronic Ulcers in Adults With Diabetes Mellitus Completed NCT01421966 Phase 3
12 Efficacy of Prontosan Solution on Chronic Ulcers Completed NCT01333670 Phase 3 Isotonic solution (saline or lactated ringer)
13 Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing Completed NCT01214811 Phase 3
14 VIITAL: A Phase 3 Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) Recruiting NCT04227106 Phase 3
15 Clinical Relevance of the Antimicrobial Resistance Testing in the Treatment of Chronic Wounds With Antiseptics Not yet recruiting NCT04172363 Phase 3 Octenisept and Serasept
16 Phase III Study Evaluating the Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds Terminated NCT02028923 Phase 3 Morphine gel
17 Effect of SACCHACHITIN on Healing of Chronic Wound ---A Clinical Trial Unknown status NCT00117364 Phase 2 SACCHACHITIN patch
18 Evaluation of the Safety and Efficacy of the Treatment of Chronic Wounds in Diabetic Foot Syndrome With the Use of Autologous Stem Cells Isolated From Adipose Tissue Unknown status NCT03865394 Phase 1, Phase 2
19 Study Assessing Safety and Efficacy of B-cure Laser Treating Diabetic Chronic Wounds Unknown status NCT01493895 Phase 1, Phase 2
20 Prospective, Placebo-controlled, Double-blind, Randomized Clinical Study to Assess the Safety and Efficacy of Topical Treatment of AR/101 Compared With for up to 28 Days, in Accelerating Granulation Tissue Formation in Chronic Wound Patients Unknown status NCT02839226 Phase 2 AR/101;Placebo
21 A Randomized, Parallel Group, Dose-Ranging, Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nexagon® in the Treatment of Subjects With a Venous Leg Ulcer Completed NCT01199588 Phase 2 Nexagon® Low Dose;Nexagon® High Dose;Nexagon® Vehicle
22 Prospective, Multicenter, Single-blind, Randomized, Controlled Clinical Trial on Safety and Efficacy of a Novel Topical Formulation Containing Erythropoietin for the Treatment of Diabetic Foot Ulcers Completed NCT02361931 Phase 1, Phase 2 A hydrogel containing erythropoietin;Hydrogel (as a part of SOC)
23 Open, Prospective, Controlled Case Series Documentation to Compare Intra-individually the Efficacy and Tolerance of Sericare® Versus Non-adhesive Wound Dressing Alone in Accelerating the Epithelialization of Skin Lesions of Patients With Epidermolysis Bullosa Hereditaria Completed NCT01294241 Phase 2 Oleogel-S10
24 Safety and Efficacy Study for the Use of Extracorporeal Shockwaves in the Treatment of Chronic Soft Tissue Wounds Completed NCT00545896 Phase 2
25 Autologous Platelet-Rich Plasma Versus Conventional Dressing Method in the Treatment of Chronic Diabetic Foot Ulcers Completed NCT04750837 Phase 2
26 Open Label Study (Phase 2) to Evaluate the Safety, Tolerance and Efficacy of a Ionic Silver and Honey Preparation to Treat Chronic Wounds of the Lower Legs Completed NCT01111695 Phase 2
27 Chronic Wounds Reference Nurse and Telematic Interconsultation Program for Pressure Ulcers in Primary Care: Evaluation of Effectiveness and Cost Reduction Completed NCT01877681 Phase 2
28 Adipose Derived Regenerative Cellular Therapy of Chronic Wounds Completed NCT02092870 Phase 2 Adipose derived stem cells
29 Feasibility and Safety and Evaluation of the Potential Efficacy of Autologous Platelet-rich Plasma in the Treatment of Vascular Venous Ulcers Compared to Moist Wound Care in a Primary Care Setting Completed NCT01817218 Phase 1, Phase 2 Platelet Rich Plasma
30 Evaluation of DermStream(tm) - an Irrigation Product for Chronic Wound Management Completed NCT00310752 Phase 1, Phase 2
31 A Phase 1/2A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Single and Repeated Doses of AUP1602-C as Topical Treatment of Diabetic Foot Ulcers Recruiting NCT04281992 Phase 1, Phase 2
32 A Prospective, Multicenter, Randomized, Controlled Clinical Investigation of PalinGen® Flow Amniotic Tissue Allograft to Assess Safety, Tolerability, and Preliminary Efficacy for the Treatment of Chronic Lower Extremity Cutaneous Ulcers Compared to Standard of Care Recruiting NCT04667416 Phase 2
33 A Phase I/II Clinical Trial To Determine Safety And Feasibility Of Using An Acellular Amniotic Fluid Application To Expedite Healing In Chronic Wounds Not yet recruiting NCT04438174 Phase 1, Phase 2 Processed Amniotic Fluid
34 Prospective Case Series on a Combination Methylene Blue, Gentian Violet, and Ovine Forestomach-derived Extracellular Matrix Dressing for Hidradenitis Suppurativa Not yet recruiting NCT04354012 Phase 2
35 A PRELIMINARY OPEN CLINICAL STUDY, TO ASSESS THE SAFETY AND EFFICACY OF RPh201 APPLIED TOPICALLY FOR THE TREATMENT OF HARD TO HEAL CHRONIC ULCERATED WOUNDS Terminated NCT01429519 Phase 1, Phase 2 RPh201, botanical drug product
36 A Double Blind, Randomized, Controlled Study, Performed in Subjects With Post Traumatic-post Surgical, Venus Insufficiency and Diabetic Hard to Heal/Chronic Wounds, to Evaluate the Safety and Efficacy of Polyheal-2 vs PolyHeal in Once Daily Regimen Terminated NCT01679678 Phase 2
37 The Observational Effects of the Topical Application of ViaNOx-H (Gaseous Nitric Oxide) on the Bio-Burden in Chronic Non-Healing Colonized Ulcers of the Lower Extremities Terminated NCT00823095 Phase 2 Nitric Oxide
38 Effect of Hematopoietic Stem Cells in Chronic Wounds Using a Pressure Sore Model: A Pilot Study on Feasibility, Safety and Potential Effects Unknown status NCT00535548 Phase 1
39 A Phase 1, Open Label, Single Dose, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Patients With Diabetic or Venous Stasis Ulcers Completed NCT00425178 Phase 1 FGF-1
40 Therapeutic Potential of Stem Cell Conditioned Medium on Chronic Ulcer Wounds : Pilot Study in Human Completed NCT04134676 Phase 1 Conditioned Media
41 To Demonstrate the Safety and Efficacy of Autologous Platelet Rich Plasma (PRP) for the Treatment of Chronic Non-Healing Ulcers Completed NCT03026855 Phase 1
42 Clinical Trial of Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Non-healing Wounds Recruiting NCT04235868 Phase 1
43 A Phase I Safety Study Using Stromal Vascular Fraction From Lipoaspirate in the Treatment of Chronic Non-healing Wounds Recruiting NCT03882983 Phase 1 Antria Cell Preparation Process
44 A Randomized, Double-Blind, Controlled Study to Evaluate the Effectiveness of the Use of Bone Marrow-Derived Mesenchymal Stem Cells (MSCs) in Fibrin in the Treatment of Chronic Wounds Terminated NCT01751282 Phase 1
45 A Randomized Study to Evaluate the Safety of Bone Marrow Aspirate Plus Cultured Bone Marrow Cells vs. Bone Marrow Aspirate Alone vs. Cultured Bone Marrow Cells Alone in the Treatment of Chronic Wounds. Terminated NCT02319720 Phase 1
46 Remote Ischemic Conditioning for Treatment of Chronic Wounds Unknown status NCT02873728
47 To Study the Effect of Organic Light Emitting Diodes (OLED) on Cultured Fibroblast Unknown status NCT01724710
48 A 12-week, Single-blind, Prospective, Randomized, Controlled, Pilot Clinical Trial to Evaluate Surface Area Reduction With Use of the MolecuLight i:X™ Imaging Device Compared to Standard Treatment of Chronic Wounds Unknown status NCT03181568
49 Laparoscopic Reinforcement Suture (LARS) on Staple-line of Duodenal Stump Using Barbed Suture in Laparoscopic Gastrectomy for Gastric Cancer: A Prospective Single Arm Phase II Study Unknown status NCT03085199
50 Assessment of Tissue Oxygenation Using Multispectral Imaging Unknown status NCT03516864

Search NIH Clinical Center for Chronic Ulcer of Skin

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Chronic Ulcer of Skin cell therapies at LifeMap Discovery.

Genetic Tests for Chronic Ulcer of Skin

Anatomical Context for Chronic Ulcer of Skin

MalaCards organs/tissues related to Chronic Ulcer of Skin:

40
Skin, Bone, Bone Marrow, Endothelial, Kidney, Heart, Liver

Publications for Chronic Ulcer of Skin

Articles related to Chronic Ulcer of Skin:

(show top 50) (show all 5085)
# Title Authors PMID Year
1
Expression of natural antimicrobial peptide beta-defensin-2 and Langerhans cell accumulation in epidermis from human non-healing leg ulcers. 54 61
16201312 2005
2
[Application of recombinant human epidermal growth factor on chronic ulcer wound]. 54 61
11826651 2002
3
Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, -2, -3, and -4) in normal and aberrant wound healing. 61 54
10414498 1999
4
Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. 61 54
9204962 1997
5
Fibronectin degradation in chronic wounds depends on the relative levels of elastase, alpha1-proteinase inhibitor, and alpha2-macroglobulin. 61 54
8601737 1996
6
Duodenal ulcer. Discovery of a new mechanism and development of angiogenic therapy that accelerates healing. 61 54
1719945 1991
7
Fat grafting and platelet-rich plasma in wound healing: a review of histology from animal studies. 61
33525977 2021
8
Development of a novel RNAi therapy: Engineered miR-31 exosomes promoted the healing of diabetic wounds. 61
33718666 2021
9
Compact electron spin resonance skin oximeter: Properties and initial clinical results. 61
33210362 2021
10
Time- and Dose-Dependent Effects of Pulsed Ultrasound on Dermal Repair in Diabetic Mice. 61
33454160 2021
11
Probiotic cellulose: Antibiotic-free biomaterials with enhanced antibacterial activity. 61
33524562 2021
12
Polymer-based biomaterials for chronic wound management: Promises and challenges. 61
33486030 2021
13
Linear polysaccharides reduce production of inflammatory cytokines by LPS-stimulated bovine fibroblasts. 61
33713903 2021
14
An Innovative National Programme for Comprehensive Chronic Wound Therapy and Its Impact on Treatment Outcomes. 61
33433726 2021
15
Incorporating a structural extracellular matrix gradient into a porcine urinary bladder matrix-based hydrogel dermal scaffold. 61
33797180 2021
16
Inhibition of miR-200b Promotes Angiogenesis in Endothelial Cells by Activating The Notch Pathway. 61
33650820 2021
17
Study protocol for a multicentre, randomised controlled trial to compare the use of the decellularised dermis allograft in addition to standard care versus standard care alone for the treatment of venous leg ulceration: DAVE trial. 61
33811051 2021
18
Skin wound healing assisted by angiogenic targeted tissue engineering: A comprehensive review of bioengineered approaches. 61
32985051 2021
19
The bactericidal efficacy of femtosecond laser-based therapy on the most common infectious bacterial pathogens in chronic wounds: an in vitro study. 61
32725427 2021
20
A Rule of Thumb for Evaluating Surface Areas of Chronic Wounds. 61
33739949 2021
21
Effectiveness of ultrasonic debridement on reduction of bacteria and biofilm in patients with chronic wounds: A scoping review. 61
33236843 2021
22
A prospective, randomized, controlled, crossover study comparing three multilayered foam dressings for the management of chronic wounds. 61
33605157 2021
23
Stem cells and growth factors-based delivery approaches for chronic wound repair and regeneration: A promise to heal from within. 61
33400933 2021
24
Antimicrobial Activity of Selected Medicinal Plants from a Sub-Saharan African Country against Bacterial Pathogens from Post-Operative Wound Infections. 61
33807402 2021
25
Restoration of the healing microenvironment in diabetic wounds with matrix-binding IL-1 receptor antagonist. 61
33772102 2021
26
Hyperbaric oxygen therapy for nonhealing wounds: Treatment results of a single center. 61
33377598 2021
27
Effect of photobiomodulation on cellular migration and survival in diabetic and hypoxic diabetic wounded fibroblast cells. 61
32483750 2021
28
miR-19a/b and miR-20a Promote Wound Healing by Regulating the Inflammatory Response of Keratinocytes. 61
32949564 2021
29
Human Wounds and its Burden: Updated 2020 Compendium of Estimates. 61
33733885 2021
30
Computationally designed pyocyanin demethylase acts synergistically with tobramycin to kill recalcitrant Pseudomonas aeruginosa biofilms. 61
33723058 2021
31
New Approach to Antifungal Activity of Fluconazole Incorporated into the Porous 6-Anhydro-α-l-Galacto-β-d-Galactan Structures Modified with Nanohydroxyapatite for Chronic-Wound Treatments-In Vitro Evaluation. 61
33803717 2021
32
Use of a superabsorbent dressing in the management of exudate in hard-to-heal wounds. 61
33688756 2021
33
Evaluation of the Effect of Platelet-Rich Fibrin on Wound Healing at Split-Thickness Skin Graft Donor Sites: A Randomized, Placebo-Controlled, Triple-Blind Study. 61
32000549 2021
34
Development of Cephradine-Loaded Gelatin/Polyvinyl Alcohol Electrospun Nanofibers for Effective Diabetic Wound Healing: In-Vitro and In-Vivo Assessments. 61
33799983 2021
35
The Effect of UK Nursing Policy on Higher Education Wound Care Provision and Practice: A Critical Discourse Analysis. 61
33706598 2021
36
Wound fluid under occlusive dressings from diabetic patients show an increased angiogenic response and fibroblast migration. 61
33707159 2021
37
Strategy for Treatment of Infected Diabetic Foot Ulcers. 61
33596041 2021
38
In Situ Forming Silk Sericin-Based Hydrogel: A Novel Wound Healing Biomaterial. 61
33729761 2021
39
Antibacterial and safety tests of a flexible cold atmospheric plasma device for the stimulation of wound healing. 61
33587156 2021
40
[Treatment of chronic hard-to-heal wounds with hyaloronic acid ester: a case series of six patients]. 61
33738631 2021
41
The effect of dermal fibroblasts and mesenchymal stem cells seeded on an amniotic membrane scaffold in skin regeneration: a case series. 61
33656768 2021
42
Reconstituting the dynamics of endothelial cells and fibroblasts in wound closure. 61
33511324 2021
43
Analysis of Rinsing Fluid during Negative Pressure Wound Therapy with Instillation: A Potential Monitoring Tool in Acute and Chronic Wound Treatment. A Pilot Study. 61
33810232 2021
44
Adaptation of Staphylococcus aureus in a Medium Mimicking a Diabetic Foot Environment. 61
33810194 2021
45
Hair Follicle Transplantation for Wound Repair. 61
32522101 2021
46
Optimization of extracellular matrix production from human induced pluripotent stem cell-derived fibroblasts for scaffold fabrication for application in wound healing. 61
33755305 2021
47
Evidence for cutaneous dysbiosis in dystrophic epidermolysis bullosa. 61
33682945 2021
48
Mesenchymal stem cells' seeded amniotic membrane as a tissue-engineered dressing for wound healing. 61
33677794 2021
49
Optimising resources: an evidence-based pathway using UrgoStart for community-based patients with wounds. 61
33719554 2021
50
BET bromodomain inhibitors regulate keratinocyte plasticity. 61
33462494 2021

Variations for Chronic Ulcer of Skin

Expression for Chronic Ulcer of Skin

Search GEO for disease gene expression data for Chronic Ulcer of Skin.

Pathways for Chronic Ulcer of Skin

Pathways related to Chronic Ulcer of Skin according to GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 TNF TIMP2 PDGFB NGF INS IL6
2
Show member pathways
13.9 VEGFA TNF TIMP2 PDGFB NGF IL6
3
Show member pathways
13.89 VEGFA TTR TNF TIMP2 PDGFB OSCAR
4
Show member pathways
13.77 VEGFA TIMP2 PDGFB NGF MMP8 MMP13
5
Show member pathways
13.61 TIMP2 PDGFB NGF IL6 FGF7 FGF2
6
Show member pathways
13.6 VEGFA TNF TIMP2 PDGFB NGF INS
7
Show member pathways
13.56 VEGFA TNF PDGFB INS FN1 FGF7
8
Show member pathways
13.49 TNF TIMP2 PDGFB NGF IL6 IL1B
9
Show member pathways
13.41 VEGFA TNF PDGFB MMP1 IL6 IL1B
10
Show member pathways
13.39 TNF TIMP2 PDGFB NGF IL6 IL1B
11
Show member pathways
13.37 TIMP2 PDGFB NGF IL6 FGF7 FGF2
12
Show member pathways
13.35 VEGFA TNF TIMP2 PDGFB NGF IL6
13
Show member pathways
13.16 PDGFB NGF INS FGF7 FGF2 EGF
14
Show member pathways
13.15 TIMP2 PDGFB NGF IL6 FN1 FGF7
15
Show member pathways
13.13 TIMP2 PDGFB NGF INS IL6 FGF7
16
Show member pathways
13 VEGFA TNF PDGFB IL6 IL1B FGF2
17
Show member pathways
12.99 VEGFA TNF PDGFB NGF INS IL6
18 12.9 VEGFA PDGFB MMP1 IL6 FN1 FGF7
19
Show member pathways
12.82 VEGFA PDGFB NGF INS FGF7 FGF2
20 12.8 VEGFA TNF PDGFB NGF INS IL1B
21
Show member pathways
12.78 PDGFB INS FGF7 FGF2 EGF
22
Show member pathways
12.74 TTR TIMP2 PDGFB MMP8 MMP13 MMP1
23 12.73 PDGFB INS FN1 FGF7 FGF2 EGF
24
Show member pathways
12.69 TNF PDGFB IL6 IL1B FN1 FGF2
25
Show member pathways
12.68 TNF TIMP2 PDGFB NGF IL6 IL1B
26
Show member pathways
12.57 VEGFA PDGFB IL6 FGF2 EGF
27 12.49 VEGFA PDGFB NGF FGF7 FGF2 EGF
28
Show member pathways
12.48 TIMP2 PDGFB NGF IL6 FGF7 FGF2
29
Show member pathways
12.42 TNF MMP13 MMP1 IL6 IL1B
30
Show member pathways
12.42 TNF INS IL6 IL1B CRP ALB
31 12.36 VEGFA TNF FN1 FGF2
32
Show member pathways
12.36 VEGFA MMP13 MMP1 FN1
33
Show member pathways
12.32 TNF TIMP2 PDGFB NGF IL6 IL1B
34 12.29 VEGFA TNF MMP1 IL6 EGF
35 12.28 VEGFA TNF NGF IL6 IL1B
36
Show member pathways
12.25 TNF IL6 IL1B FN1
37 12.16 VEGFA TNF PDGFB IL1B
38 12.15 TNF IL6 IL1B FN1
39 12.04 VEGFA INS IL6 EGF
40 12.02 INS IL6 IL1B FN1
41 12.02 VEGFA TNF IL6 IL1B FN1
42 12 TNF IL6 IL1B FN1
43
Show member pathways
12 TNF TIMP2 MMP8 MMP13 MMP1 ELANE
44 11.96 VEGFA TNF MMP1 IL6 IL1B
45 11.95 PDGFB INS IL6 FN1 FGF2 EGF
46 11.89 VEGFA PDGFB NGF FGF2 EGF
47 11.86 VEGFA TNF MMP1 IL6 IL1B FN1
48
Show member pathways
11.81 TNF IL6 IL1B
49 11.81 TNF IL6 IL1B
50 11.8 TNF IL6 IL1B

GO Terms for Chronic Ulcer of Skin

Cellular components related to Chronic Ulcer of Skin according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.91 VEGFA TTR TNF TIMP2 PDGFB NGF
2 cell surface GO:0009986 9.88 VEGFA TNF TIMP2 PDGFB OSCAR ELANE
3 collagen-containing extracellular matrix GO:0062023 9.83 TIMP2 PDGFB MMP8 FN1 ELANE
4 endoplasmic reticulum lumen GO:0005788 9.77 PDGFB INS IL6 FN1 ALB
5 extracellular matrix GO:0031012 9.73 VEGFA TIMP2 MMP8 MMP13 MMP1 FN1
6 tertiary granule lumen GO:1904724 9.63 TIMP2 OSCAR MMP8
7 specific granule lumen GO:0035580 9.62 TIMP2 OSCAR MMP8 ELANE
8 extracellular region GO:0005576 9.62 VEGFA TTR TNF TIMP2 PDGFB OSCAR
9 platelet alpha granule lumen GO:0031093 9.55 VEGFA PDGFB FN1 EGF ALB

Biological processes related to Chronic Ulcer of Skin according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.36 VEGFA TTR PDGFB INS IL6 IL1B
2 positive regulation of transcription, DNA-templated GO:0045893 10.19 TNF PDGFB IL6 IL1B FGF7 FGF2
3 neutrophil degranulation GO:0043312 10.13 TTR TIMP2 OSCAR MMP8 ELANE
4 MAPK cascade GO:0000165 10.08 TNF PDGFB IL1B FGF7 FGF2 EGF
5 negative regulation of gene expression GO:0010629 10.07 VEGFA TNF PDGFB MMP8 FGF2
6 positive regulation of cell migration GO:0030335 10.06 VEGFA PDGFB INS IL1B EGF
7 positive regulation of cell proliferation GO:0008284 10.06 VEGFA PDGFB INS IL6 IL1B FN1
8 cytokine-mediated signaling pathway GO:0019221 10.05 VEGFA TNF MMP1 IL6 IL1B FN1
9 positive regulation of protein phosphorylation GO:0001934 10.04 VEGFA TNF IL1B FGF7 FGF2
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.02 VEGFA TNF PDGFB FGF2
11 leukocyte migration GO:0050900 10.01 TNF MMP1 FN1 ELANE
12 positive regulation of NF-kappaB transcription factor activity GO:0051092 10 TNF INS IL6 IL1B
13 cellular protein metabolic process GO:0044267 10 TTR MMP13 MMP1 INS IL6 FN1
14 activation of MAPK activity GO:0000187 9.97 TNF IL1B FGF2 EGF
15 platelet degranulation GO:0002576 9.97 VEGFA PDGFB FN1 EGF ALB
16 positive regulation of interleukin-6 production GO:0032755 9.95 TNF MMP8 IL6 IL1B
17 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.95 VEGFA PDGFB IL6 FGF7 EGF
18 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.94 VEGFA TNF NGF IL6
19 positive regulation of endothelial cell proliferation GO:0001938 9.92 VEGFA PDGFB FGF2 EGF
20 extracellular matrix organization GO:0030198 9.92 TTR TNF PDGFB MMP8 MMP13 MMP1
21 response to wounding GO:0009611 9.91 PDGFB FN1 FGF7
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.91 TNF PDGFB IL6 ELANE
23 positive regulation of interleukin-8 production GO:0032757 9.91 TNF IL6 IL1B ELANE
24 positive regulation of protein kinase B signaling GO:0051897 9.91 VEGFA TNF PDGFB INS FGF7 FGF2
25 regulation of insulin secretion GO:0050796 9.9 TNF IL6 IL1B
26 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.9 VEGFA TNF IL6
27 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.9 VEGFA TNF NGF
28 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.89 TNF MMP8 IL1B
29 positive regulation of endothelial cell migration GO:0010595 9.89 VEGFA FGF2 EGF
30 positive regulation of epithelial cell proliferation GO:0050679 9.89 VEGFA FGF7 FGF2
31 extracellular matrix disassembly GO:0022617 9.89 TIMP2 MMP8 MMP13 MMP1 ELANE
32 positive regulation of protein complex assembly GO:0031334 9.88 VEGFA TNF MMP1
33 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.88 TNF PDGFB FGF2
34 positive regulation of blood vessel endothelial cell migration GO:0043536 9.88 VEGFA PDGFB FGF2
35 positive chemotaxis GO:0050918 9.88 VEGFA PDGFB FGF7 FGF2
36 positive regulation of cell division GO:0051781 9.88 VEGFA PDGFB IL1B FGF7 FGF2
37 positive regulation of nitric oxide biosynthetic process GO:0045429 9.87 TNF MMP8 IL1B
38 collagen catabolic process GO:0030574 9.87 MMP8 MMP13 MMP1
39 acute-phase response GO:0006953 9.87 INS IL6 FN1 CRP
40 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.85 TNF PDGFB FGF2
41 positive regulation of DNA binding GO:0043388 9.84 NGF MMP8 EGF
42 positive regulation of mitotic nuclear division GO:0045840 9.84 PDGFB INS IL1B EGF
43 negative regulation of neurogenesis GO:0050768 9.83 TNF IL6 IL1B
44 positive regulation of protein autophosphorylation GO:0031954 9.83 VEGFA PDGFB INS
45 positive regulation of glial cell proliferation GO:0060252 9.81 TNF IL6 IL1B
46 negative regulation of lipid catabolic process GO:0050995 9.8 TNF INS IL1B
47 positive regulation of DNA biosynthetic process GO:2000573 9.79 VEGFA PDGFB FGF2
48 negative regulation of lipid storage GO:0010888 9.77 TNF IL6 CRP
49 regulation of establishment of endothelial barrier GO:1903140 9.73 TNF IL1B
50 vascular endothelial growth factor production GO:0010573 9.73 TNF IL6 IL1B

Molecular functions related to Chronic Ulcer of Skin according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.06 VEGFA TTR TNF PDGFB INS FN1
2 integrin binding GO:0005178 9.73 TIMP2 IL1B FN1 FGF2
3 cytokine activity GO:0005125 9.72 VEGFA TNF IL6 IL1B FGF2
4 endopeptidase activity GO:0004175 9.67 MMP8 MMP13 MMP1 ELANE
5 heparin binding GO:0008201 9.65 VEGFA FN1 FGF7 FGF2 ELANE
6 collagen binding GO:0005518 9.63 PDGFB MMP13 FN1
7 chemoattractant activity GO:0042056 9.46 VEGFA PDGFB FGF7 FGF2
8 protease binding GO:0002020 9.35 TNF TIMP2 INS FN1 ELANE
9 growth factor activity GO:0008083 9.17 VEGFA PDGFB NGF IL6 FGF7 FGF2

Sources for Chronic Ulcer of Skin

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....